Merck Sharp + Dohme Corp.

James Patrick Roane

Yeon-Hee Lim

Jianming Bao

Rose Yen

Cedric Lorenz Hugelshofer

Jillian R Sanzone

Samantha E Shockley

Victor W Mak

Fa-Xiang Ding

Eric Ashley

Chen Cheng

Emma Helen Southgate

Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

Diacylglyceride O-acyltransferase 2 inhibitors

Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors

Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors

Invented are compounds of Formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

Preparation of benzimidazolone derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors

Growing community of inventors

Brisbane, CA, United States of America

James Patrick Roane